Immune checkpoint inhibitors for first-line treatment of advanced esophageal squamous cell carcinoma.

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2024-09-13 DOI:10.1016/j.medj.2024.05.016

Maria Alsina, Tania Fleitas-Kanonnikoff

引用次数: 0

Abstract

Immunotherapy has revolutionized the treatment landscape of esophageal squamous cell carcinoma. He et al. present the final results of the randomized phase 3 ESCORT-1st trial, confirming positive survival outcomes when adding the anti-PD1 inhibitor camrelizumab to first-line chemotherapy treatment in Chinese patients with esophageal squamous cell cancer.¹.

查看原文本刊更多论文

免疫检查点抑制剂用于晚期食管鳞状细胞癌的一线治疗。

免疫疗法彻底改变了食管鳞状细胞癌的治疗格局。贺建奎等人公布了随机三期ESCORT-1st试验的最终结果，证实在中国食管鳞癌患者的一线化疗中加入抗PD1抑制剂坎瑞珠单抗可获得积极的生存结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.